Login to Your Account



Pharma: Other News To Note


Friday, March 23, 2012
• GlaxoSmithKline plc, of London, said it plans to invest more than £500 million (US$790.9 million) in its UK manufacturing sites to increase production of key active ingredients for its pharmaceutical products and vaccines. The company said it will build a £350 million biopharmaceutical manufacturing facility at Ulverston, Cumbria, and invest more than £100 million across two manufacturing sites in Scotland.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription